Key Quantitative Figures and Financial Results

The Board of Directors met on May 27, 2026, and approved the following:

1. Financial Results Approval:

  • Approved the Audited Standalone and Consolidated Financial Results for the quarter and financial year ended March 31, 2026.
  • The statutory auditors, SSJNB & Co., Chartered Accountants (Firm Regn. No. 0139768), issued an audit report with an unmodified opinion on both sets of results.

Standalone Financial Highlights (FY 2025-26):

  • Total Assets: Increased to ₹39,105.51 lakhs from ₹35,056.39 lakhs in the previous year.
  • Property, Plant & Equipment: ₹7,672.89 lakhs (Previous: ₹7,094.80 lakhs).
  • Capital Work-in-Progress: ₹742.42 lakhs (Previous: ₹278.58 lakhs).
  • Inventories: ₹11,612.85 lakhs (Previous: ₹10,277.80 lakhs).
  • Trade Receivables: ₹9,636.24 lakhs (Previous: ₹9,484.78 lakhs).
  • Total Equity: ₹10,409.91 lakhs (Previous: ₹9,882.46 lakhs).
  • Total Borrowings (Non-Current + Current): ₹15,374.79 lakhs (Previous: ₹14,461.17 lakhs).
  • Net Cash Flow from Operating Activities: ₹3,044.13 lakhs (Previous: ₹2,031.43 lakhs).
  • Profit Before Tax: ₹636.52 lakhs (Previous: ₹573.23 lakhs).

Consolidated Financial Highlights (Q4 FY26):

  • Revenue from Operations: ₹8,407.57 lakhs (Q3 FY26: ₹8,768.97 lakhs; Q4 FY25: ₹8,187.62 lakhs).
  • Profit Before Tax: ₹321.74 lakhs (Q3 FY26: ₹179.06 lakhs; Q4 FY25: ₹259.34 lakhs).
  • Net Profit: ₹360.36 lakhs (Q3 FY26: ₹179.06 lakhs; Q4 FY25: ₹541.85 lakhs).
  • EPS (Basic & Diluted): ₹2.26 (Q3 FY26: ₹1.12; Q4 FY25: ₹3.40).

Consolidated Financial Highlights (FY 2025-26):

  • Total Income: ₹31,358.91 lakhs (FY 2024-25: ₹30,528.62 lakhs).
  • Profit Before Tax: ₹593.38 lakhs (FY 2024-25: ₹513.75 lakhs).
  • Net Profit: ₹632.00 lakhs (FY 2024-25: ₹723.67 lakhs).
  • EPS (Basic & Diluted): ₹3.95 (FY 2024-25: ₹4.56).
  • Paid-up Equity Share Capital: ₹1,592.09 lakhs.
  • Other Equity: ₹6,630.65 lakhs (Previous: ₹6,149.50 lakhs).

2. Dividend Declaration:

  • The Board recommended a dividend of ₹1.20 per equity share (face value ₹10 each), constituting a 12% payout.
  • This is subject to approval by the shareholders at the ensuing Annual General Meeting (AGM).

3. Appointments:

  • Internal Auditors: Appointed Murugesh & Co., Chartered Accountants for FY 2025-26.
  • Cost Auditors: Appointed G.N.V & Associates, Cost Accountants for FY 2025-26.
  • Company Secretary & Compliance Officer: Appointed Mr. Shreepada ML (Membership No. A66681) with effect from May 27, 2026, replacing Mr. Abdul Basith who resigned effective May 11, 2026. Mr. Shreepada has over 7 years of experience.

4. Employee Stock Option Plan (ESOP):

  • Approved the grant of 500,000 stock options to employees under the "Bal Pharma Limited - Employee Stock Option Plan-2025".

5. Preferential Issue:

  • Approved a preferential issue of 1,000,000 warrants to the promoters of the company.
  • The conversion price will be the applicable price as per regulations.
  • Decided to seek shareholder approval for this issue through a postal ballot.

Dates of Action

  • Board Meeting Date: May 27, 2026 (commenced at 4:30 PM, concluded at 5:30 PM).
  • Financial Period Ended: March 31, 2026.
  • Appointment Effective Date: May 27, 2026 (for Mr. Shreepada ML).
  • Resignation Effective Date: May 11, 2026 (for Mr. Abdul Basith).

Parties Involved

  • Statutory Auditors: SSJNB & Co., Chartered Accountants.
  • Internal Auditors: Murugesh & Co., Chartered Accountants.
  • Cost Auditors: G.N.V & Associates, Cost Accountants.
  • New Appointee: Mr. Shreepada ML, Company Secretary & Compliance Officer.
  • Previous Officer: Mr. Abdul Basith (resigned).
  • Subsidiaries (for consolidation): Lifezen Healthcare Private Limited, Balance Clinics LLP, Bal Research Foundation, Aurum Research & Analytical Solutions Private Limited.
  • Regulators: BSE Limited, National Stock Exchange of India Ltd., SEBI.

Capital Structure Impact

  • The grant of 500,000 ESOPs and the proposed issue of 1,000,000 warrants to promoters will potentially lead to dilution of equity upon conversion/exercise. The exact impact on share capital will depend on the final conversion terms of the warrants and the exercise of ESOPs.

Cash Flow Implications

  • Dividend payout, if approved by shareholders, will result in a cash outflow. The amount for the recommended dividend is not quantified in the disclosure beyond the per-share amount.
  • The issuance of warrants will result in a cash inflow upon conversion.